Takeda Pharmaceutical (TAK) said Wednesday that the non-profit organization Hema-Quebec will begin reimbursing HyQvia for patients with primary or secondary humoral immunodeficiencies aged two and older starting Jan. 30 in Quebec, Canada.
The company said HyQvia, a subcutaneous immune globulin infusion indicated for immune system deficiencies that increase infection risk, received Health Canada approval for adults in 2022 and pediatric patients in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.